Pain Clinical Trial
Official title:
Phase 4 Study, Open, Observational, to Evaluate the Safety and Tolerability of Hydrochloride Controlled-release Oxycodone in Moderate and Severe Postoperative Pain in Oncologic Head and Neck Surgery.
The hypothesis of this study is that controlled release oxycodone can be safe and well tolerated for the control of postoperative pain in surgery for head and neck cancer. The primary objective is to study the safety and the incidence and severity of adverse effects, and the secondary objective is to evaluate the analgesic efficacy and identify the frequency of use of rescue medication and the prescribing physician's opinion about the quality of postoperative analgesia with oxycodone controlled release in oncologic surgery of the head and neck.
Phase IV clinical trial, observational, prospective, open approved by the Research Ethics
Committee of the National Cancer Institute José Alencar Gomes da Silva - INCA, Brazil (no.
10/2010). The Instrument of Consent is signed by all patients.
Eighty-three patients will be included. Ages between 18 and 70 years both genders, 2 and 3
American Society of Anesthesiologists physical status, which present moderate to severe pain
source postoperative surgical oncology, head and neck, medium and large, elective,
non-emergency, able to swallow tablets whole (not chewed, broken or crushed) in the
immediate postoperative period after recovery of cognitive functions. Will be excluded
pregnant or breastfeeding, allergic to oxycodone and other opioids, gastrectomized or
colostomized, asthmatics with severe organ dysfunction, with a history or suspected
paralytic ileus, or a history psychiatric disorders, severe respiratory depression, patients
who are receiving opioid analgesics in baseline, history of abuse of alcohol and illicit
drugs, patients who present in plasma glutamic oxaloacetic transaminase above 48 U / l (men)
and 40 U / I (women) and / or glutamic pyruvic transaminase above 53 U / l (men) and 40 U /
I (women) and patients who present plasma creatinine above 1.7 mg / dl and / or urea above
65 mg / dl. All patients will be assessed preoperatively seven to one day before surgery
(visit 1) when will the signed consent form, proceeded to pre-anesthetic evaluation and
blood will be collected for laboratory tests: complete blood count, β-human chorionic
gonadotropin(women), glutamic oxaloacetic transaminase, glutamic pyruvic transaminase,
creatinine and urea.
In the immediate postoperative period (visit 2), the pain will be assessed by verbal numeric
scale (VNS) and when pain is moderate to severe (≥ 4 EVN) and the patient is lucid and able
to swallow, will start orally controlled-release oxycodone (Oxycontin, Zodiac
Pharmaceuticals, Brazil) at a dose of 20 mg (tablets whole without crushing or division),
administered by the investigator. Every 12 hours and a subsequent period of 48 hours after
the first dose of oxycodone controlled-release, the pain will be evaluated again, and the
occurrence and intensity of adverse events (visits 3, 4, 5 and 6 respectively 12 , 24, 36
and 48 hours after the first dose of oxycodone). The doses of controlled-release oxycodone
will be standardized as follows: on the first day postoperatively, 40 mg / day divided into
20 mg of 12 in 12 hours and in the second postoperative day, 20 mg / day divided into 10 mg
of 12 in 12 hours.
The rescue medication will be used non opioids analgesics as paracetamol, dipyrone,
diclofenac or tenoxicam, only after the first administration of controlled-release oxycodone
postoperatively. During the visits described above will be annotated to rescue analgesia and
its frequency, should it ever be used between doses of oxycodone.
Between post-operative 7 and 13 days will be held the visit 7, which will be evaluated pain
intensity (EVN), the occurrence and severity of adverse effects, and the investigator's
opinion about treatment. Finally, the patient's blood will be collected to perform the same
tests listed at visit 1, except β-human chorionic gonadotropin (women), and the study was
terminated.
Sample Size and Statistical Analysis
When considering the occurrence of nausea of 25% as a safety parameter, assessed by
literature data, the number of patients required will be 72. Taking into consideration a
dropout of about 20% will require 86 patients in total (to an accuracy of 10%, around the
percentage confidence interval (CI) 95%). The study of normal age variable will be conducted
with the test Kolmogorov - Smirnov. The Friedman test is used to compare medians of pain
intensity from visit 2 to visit 7. The Dunn test will be used for post-hoc comparisons
(between two) of median pain intensity (p <0.001 - significant). The McNemar test for
pairwise comparisons of proportions will be employed for comparisons of adverse events
(visits 4, 5, 6 and 7 with respect to visit 3) (p <0.05 = significant). The remaining data
will be presented by frequency.
;
Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05559255 -
Changes in Pain, Spasticity, and Quality of Life After Use of Counterstrain Treatment in Individuals With SCI
|
N/A | |
Completed |
NCT04748367 -
Leveraging on Immersive Virtual Reality to Reduce Pain and Anxiety in Children During Immunization in Primary Care
|
N/A | |
Terminated |
NCT04356352 -
Lidocaine, Esmolol, or Placebo to Relieve IV Propofol Pain
|
Phase 2/Phase 3 | |
Completed |
NCT05057988 -
Virtual Empowered Relief for Chronic Pain
|
N/A | |
Completed |
NCT04466111 -
Observational, Post Market Study in Treating Chronic Upper Extremity Limb Pain
|
||
Recruiting |
NCT06206252 -
Can Medical Cannabis Affect Opioid Use?
|
||
Completed |
NCT05868122 -
A Study to Evaluate a Fixed Combination of Acetaminophen/Naproxen Sodium in Acute Postoperative Pain Following Bunionectomy
|
Phase 3 | |
Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
Completed |
NCT03273114 -
Cognitive Functional Therapy (CFT) Compared With Core Training Exercise and Manual Therapy (CORE-MT) in Patients With Chronic Low Back Pain
|
N/A | |
Enrolling by invitation |
NCT06087432 -
Is PNF Application Effective on Temporomandibular Dysfunction
|
N/A | |
Completed |
NCT05508594 -
Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001
|
Phase 2/Phase 3 | |
Recruiting |
NCT03646955 -
Partial Breast Versus no Irradiation for Women With Early Breast Cancer
|
N/A | |
Active, not recruiting |
NCT03472300 -
Prevalence of Self-disclosed Knee Trouble and Use of Treatments Among Elderly Individuals
|
||
Completed |
NCT03678168 -
A Comparison Between Conventional Throat Packs and Pharyngeal Placement of Tampons in Rhinology Surgeries
|
N/A | |
Completed |
NCT03931772 -
Online Automated Self-Hypnosis Program
|
N/A | |
Completed |
NCT03286543 -
Electrical Stimulation for the Treatment of Pain Following Total Knee Arthroplasty Using the SPRINT Beta System
|
N/A | |
Completed |
NCT02913027 -
Can We Improve the Comfort of Pelvic Exams?
|
N/A | |
Terminated |
NCT02181387 -
Acetaminophen Use in Labor - Does Use of Acetaminophen Reduce Neuraxial Analgesic Drug Requirement During Labor?
|
Phase 4 | |
Recruiting |
NCT06032559 -
Implementation and Effectiveness of Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment
|
Phase 3 | |
Active, not recruiting |
NCT03613155 -
Assessment of Anxiety in Patients Treated by SMUR Toulouse and Receiving MEOPA as Part of Their Care
|